Oragenics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on April 30, 2008, covering corporate governance events that occurred on April 25, 2008, and April 8, 2008.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Board Appointment: Effective April 25, 2008, Dr. Marc K. Siegel was appointed as a new Director.
- Board Composition: The Board now consists of six directors, three of whom are independent.
- Compensation: Dr. Siegel was awarded 65,000 stock options with an exercise price of $0.76, which vest immediately.
- Prior Action: Mr. Kevin H. Sills was appointed as an independent director on April 8, 2008, as previously reported.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of outstanding shares to assess the dilution impact of the 65,000 options granted to Dr. Siegel.
- Confirm the current composition of the Board of Directors and the independence status of all members.
- Review the press release dated April 28, 2008 (Exhibit 99.1) for additional context on the appointments.